Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Naz Rahman reiterated a Buy rating on Nuvectis Pharma (NVCT) with a $30.00 price target. This follows H.C. Wainwright also maintaining a Buy rating with a higher $39.00 target. Rahman, who covers the healthcare sector, has a historical success rate of 36.93% on recommended stocks.
In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $30.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Rahman covers the Healthcare sector, focusing on stocks such as Nuvectis Pharma, Vertex Pharmaceuticals, and Vivani Medical. According to TipRanks, Rahman has an average return of -7.5% and a 36.93% success rate on recommended stocks.
In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $39.00 price target.